Literature DB >> 27473610

Fentanyl and a Novel Synthetic Opioid U-47700 Masquerading as Street "Norco" in Central California: A Case Report.

Patil Armenian1, Alexander Olson2, Andres Anaya3, Alicia Kurtz3, Rawnica Ruegner3, Roy R Gerona2.   

Abstract

In 2013 and 2014, more than 700 deaths were attributed to fentanyl and fentanyl analogues in the United States. Of recent concern is the cluster of unintentional fentanyl overdoses because of tablets thought to be "Norco" purchased on the street in Northern California. U-47700 (trans-3,4-dichloro-N-[2-(dimethyl-amino)cyclohexyl]-N-methylbenz-amide) is a nonfentanyl-based synthetic opioid with 7.5 times the binding affinity of morphine to μ-opioid. We report a case of fentanyl and U-47700 intoxication from what was thought to be illicitly purchased Norco. A 41-year-old woman presented to the emergency department (ED) for altered mental status shortly after ingesting 3 beige Norco pills bearing a Watson imprint. She had pinpoint pupils and respiratory depression, which reversed after 0.4 mg naloxone administration intravenously. She had complete recovery and was discharged from the ED after a 4-hour observation period. Serum testing with liquid chromatography-quadrupole time-of-flight mass spectrometry (LC 1260 QTOF/MS 6550; Agilent, Santa Clara, CA) confirmed the presence of the medications the patient reported receiving, and additionally fentanyl (15.2 ng/mL) and U-47700 (7.6 ng/mL). In this case report, street Norco purchased in Central California resulted in altered mental status requiring naloxone reversal because of fentanyl and the novel synthetic opioid U-47700. Because these compounds are not detected by routine urine drug testing and physical examination findings are similar to those of a traditional opioid toxidrome, emergency providers should use the patient's history and other circumstantial details to aid in diagnosis. In cases with suspicion of opioid or opioid analogue cause, we recommend that emergency providers contact their local poison control center, medical toxicologist, or public health department to aid in the investigation.
Copyright © 2016 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27473610     DOI: 10.1016/j.annemergmed.2016.06.014

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  19 in total

1.  Combating Substandard and Counterfeit Medicines by Securing the Pharmaceutical Supply Chain: The Drug Supply Chain Security Act (DSCSA) of 2013.

Authors:  Phuong Le; Laurie Grund; John Marwa; Wuraola Ojo; John Otts; Farhia Arab
Journal:  Innov Pharm       Date:  2018-07-16

2.  Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace.

Authors:  Michael H Baumann; Susruta Majumdar; Valerie Le Rouzic; Amanda Hunkele; Rajendra Uprety; Xi Ping Huang; Jin Xu; Bryan L Roth; Ying-Xian Pan; Gavril W Pasternak
Journal:  Neuropharmacology       Date:  2017-08-12       Impact factor: 5.250

3.  Barriers to accurately assessing prescription opioid misuse on surveys.

Authors:  Joseph J Palamar
Journal:  Am J Drug Alcohol Abuse       Date:  2018-09-19       Impact factor: 3.829

Review 4.  Interpol review of controlled substances 2016-2019.

Authors:  Nicole S Jones; Jeffrey H Comparin
Journal:  Forensic Sci Int Synerg       Date:  2020-05-24

5.  Detection of Fentanyl Analogs and Synthetic Opioids in Real Hair Samples.

Authors:  Alberto Salomone; Joseph J Palamar; Rachele Bigiarini; Enrico Gerace; Daniele Di Corcia; Marco Vincenti
Journal:  J Anal Toxicol       Date:  2019-05-01       Impact factor: 3.367

6.  Fentanyl and fentanyl-analog involvement in drug-related deaths.

Authors:  Zheng Dai; Marie A Abate; Gordon S Smith; James C Kraner; Allen R Mock
Journal:  Drug Alcohol Depend       Date:  2019-01-09       Impact factor: 4.492

7.  Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic.

Authors:  Nadia Fairbairn; Phillip O Coffin; Alexander Y Walley
Journal:  Int J Drug Policy       Date:  2017-07-04

Review 8.  Blood concentrations of new synthetic opioids.

Authors:  Piotr Adamowicz; Karolina Nowak
Journal:  Int J Legal Med       Date:  2021-10-22       Impact factor: 2.686

9.  Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats.

Authors:  Michael T Truver; Christina R Smith; Nancy Garibay; Theresa A Kopajtic; Madeleine J Swortwood; Michael H Baumann
Journal:  Neuropharmacology       Date:  2020-06-10       Impact factor: 5.250

10.  Toxicosurveillance of novel opioids: just screening tests may not be enough.

Authors:  A Salomone; J J Palamar
Journal:  Am J Drug Alcohol Abuse       Date:  2021-05-19       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.